{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03194542\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"ACE-536-MF-001","nct_id":"NCT03194542","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ace-536-mf-001-nct03194542. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.","label":"Luspatercept in subjects with MPN-associated myelofibrosis","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-07-18","type":"ACTUAL"},"conditions":["Primary Myelofibrosis","Anemia"],"enrollment":{"count":95,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Luspatercept","otherNames":["ACE-536"],"type":"DRUG"}],"last_update":"2023-08-24","lead_sponsor":"Celgene","official_title":"A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-07-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period","timeFrame":"Any consecutive \"rolling\" 84-day period from Day 1 through and including Day 168"}],"references":[{"citation":"Gerds AT, Harrison C, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji R, Bose P, Kremyanskaya M, Mead AJ, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi AC, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv. 2024 Sep 10;8(17):4511-4522. doi: 10.1182/bloodadvances.2024012939.","pmid":"38820422","type":"DERIVED"}],"start_date":{"date":"2017-11-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence","url":"https://clinicaltrials.gov/study/NCT03194542"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ace-536-mf-001-nct03194542"}